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Background: Gonadotrophins are used routinely for follicular stimulation during ovarian induction and assisted
reproduction techniques. Developments in recombinant follicle-stimulating hormone preparations and their
injection devices have improved patient quality of life by enabling patients to self-administer treatment at home.
The objective of this study was to investigate patient experiences of learning to use and overall satisfaction with
the follitropin-alpha (Gonal-f) filled-by-mass (FbM) prefilled pen.
Methods: This questionnaire-based survey study was conducted in 23 fertility centres in Japan over a period of 14
months. Patients who were receiving fertility treatment with the follitropin-alpha (FbM) prefilled pen were asked to
complete a questionnaire to assess their satisfaction, ease of learning and use, and injection site pain following treatment.
Results: A total of 663 women participated in the study. The majority of patients found the instructions for administering
follitropin-alpha with the prefilled pen easy to understand (83.0%; n = 546/658) and patients found that a hands-on
demonstration by a nurse or doctor was the most useful tool for learning to use the follitropin-alpha (FbM) prefilled pen
(80.0%; n = 497/621). Forty-eight percent (n = 318) of patients in the study had previous experience with different types
of fertility medications and the majority of these patients found the follitropin-alpha (FbM) prefilled pen easier to use
(75.1%; n = 232/309) and less painful (89.0%; n = 347/390) than their previous medication. The majority (80.2%; n = 521/
650) of patients reported overall satisfaction with the follitropin-alpha (FbM) prefilled pen.
Conclusions: The follitropin-alpha (FbM) prefilled pen is an easy-to-use injection device according to this
questionnaire-based survey. Patients who had experience of different types of fertility medication preferred the
follitropin-alpha (FbM) prefilled pen to other injection devices.
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Table 1 Ease of learning*




Total no. patients who
responded to question
Were the instructions for administering the
follitropin-alpha pen easy to understand?
Yes 546 83.0 658
OK 106 16.1 658
No 6 0.9 658
N/A 5
Which tools did you use to learn how to




Very useful 582 91.5 636
Useful 52 8.2 636
Not useful 2 0.3 636
N/A 27
Leaflet Very useful 421 71.1 592
Useful 161 27.2 592
Not useful 10 1.7 592
N/A 71
DVD Very useful 160 47.3 338
Useful 135 39.9 338
Not useful 43 12.7 338
N/A 325
Web Very useful 18 26.1 69
Useful 21 30.4 69
Not useful 30 43.5 69
N/A 594
Which of the tools did you find was the





Leaflet 89 14.3 621
DVD 35 5.6 621
Web 0 0.0 621
N/A 42
How easy was it for you to understand
how to use the follitropin-alpha pen?
1 (very difficult) 3 0.5 658
2 4 0.6 658
3 11 1.7 658
4 5 0.8 658
5 26 4.0 658
6 21 3.2 658
7 49 7.4 658
8 152 23.1 658
9 128 19.5 658
10 (very easy) 259 39.4 658
N/A 5
Based on your experience of learning,
would you ecommend the follitropin-alpha
pen to another woman who was considering
fertility treatment?
Yes 611 94.9 644
No 33 5.1 644
N/A 19
Have you used any of the following
medications in the past? If yes, please
select the medication that you most
recently used†
Follistim pen 130 40.9 318
Follistim vial 53 16.7 318
hMG 119 37.4 318
Gonapure 6 1.9 318
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Table 1 Ease of learning* (Continued)
Folyrmon P 10 3.1 318
N/A or no previous use 348
Which treatment did you find to be the
easiest to use: the follitropin-alpha pen or
a previous treatment medication?
Follitropin-alpha pen 232 75.1 309
Same ease of use 70 22.7 309
Other product 7 2.3 309
N/A or no use 354
*Patients were asked a series of questions to assess how easy it was to learn to use the follitropin-alpha (FbM) prefilled pen. N/A = patient did not answer the
question. † Includes multiple answers.
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Gonadotrophins are routinely used for follicular stimula-
tion in ovarian induction (OI) and assisted reproduction
techniques (ART). Follicle-stimulating hormone (FSH) and
HMG (human menopausal gonadotrophin) are used dur-
ing OI and ART to stimulate the growth and recruitment
of immature follicles in the ovary [1,2]. FSH is currently
available in two preparations: urinary FSH (u-FSH) and re-
combinant FSH (r-FSH). HMG and u-FSH are extracted
from the urine of postmenopausal women, whereas r-FSH,
which became available in 1996, is produced using recom-
binant DNA technology.
Daily injections of recombinant peptides are required
for several conditions such as growth hormone for growth
deficiencies in children. Injections that are required on a
long-term, regular basis must be quick, simple and as pain
free as possible to ensure patients comply with treatment
[3]. During treatment for OI and ART, gonadotrophins
have to be injected daily for an average of 10 days and are
often reconstituted from freeze-dried peptides. Tradition-
ally, HMG has been administered as an intramuscular in-
jection. However, the development of the higher purity
FSH preparations has enabled subcutaneous injections to
be used. Advances in FSH formulations have been accom-
panied by progress in the devices available for the delivery
of the peptides. The subcutaneous administration systems
that have evolved for r-FSH generally enable self-
administration at home and have led to improvements in
patient satisfaction and quality of life [4-10].
It is well established that treatment outcomes can be
affected by patient compliance, and that compliance is
related to treatment choice and method of administration.
For example, therapies that are easier to administer and
cause less injection site pain are associated with higher
rates of compliance than those that are difficult to adminis-
ter and cause pain [4,7,10,11]. It has been demonstrated
previously that patients, who receive subcutaneous injec-
tions for IVF, reported experiencing less pain than those
who receive intramuscular injections [12]. Moreover, it has
been documented that patients can make errors in the re-
constitution of freeze-dried peptides for self-administration
at home, and pregnancy rates are higher in patients who
prepare and administer injections correctly [10].The follitropin-alpha (Gonal-f) filled-by mass (FbM)
prefilled pen (Merck Serono SA, Geneva, Switzerland, an
affiliate of Merck KGaA, Darmstadt, Germany) is a ready-
to-use disposable injection delivery device. The pen con-
tains premixed follitropin alfa filled-by-mass, which pro-
vides more accurate and consistent dosing than r-FSH
filled-by-bioassay [8]. Routine use of follitropin-alpha in
ART was well accepted by patients participating in a
German observational study; in addition, study patients
required less training to use follitropin-alpha pens com-
pared with vials or ampoules [13]. More importantly from
a compliance point of view, patients preferred the prefilled
pen compared with another loadable device (a reusable
pen with loadable cartridges) [13]. Results from two other
studies suggest that the follitropin-alpha prefilled pen had
higher patient and nurse acceptance than the follitropin-
beta pen (supplied in glass cartridges to be used with a
pen injector; Puregon; Organon, Roseland, NJ, USA) [14].
Another survey found that more patients preferred the
follitropin-alpha prefilled pen to the follitropin-beta cart-
ridge pen or urofollitropin (Ferring Pharmaceuticals,
Suffern, NY, USA) administered with a needle-free recon-
stitution device and conventional syringe. Additionally,
patients stated that the ease of use, dosing mechanism and
reduced potential for dosing errors were the factors that
they found most important [15].
The current study was designed to evaluate overall pa-
tient satisfaction, ease of learning and use, and injection
site pain associated with the follitropin-alpha (FbM) pre-
filled pen. A secondary comparison was made with other
systems of gonadotrophin administration. The study—
which involved over 650 patients treated at 23 Japanese
fertility centres—was the largest study of patient prefer-
ence to be performed in Japan.
Methods
Study design
This was a questionnaire-based survey conducted in 23
clinics certified by the Japanese Institution for Standardis-
ing Assisted Reproductive Technology (JISART). JISART
aims to achieve high standards of practice in fertility treat-
ments by implementing a quality management system, with
the ultimate goal of improving the quality of patient care.
Table 2 Ease of use and level of satisfaction*




Total no. patients who
responded to question
How easy did you find the self-injection of the follitropin-alpha
pen?
Very easy 514 79.0 651
A little difficult 125 19.2 651
Difficult 11 1.7 651
Very difficult 1 0.2 651
N/A 12
How easy was it for you to use the follitropin-alpha pen? 1 ( very difficult) 5 0.8 651
2 4 0.6 651
3 7 1.1 651
4 8 1.2 651
5 24 3.7 651
6 7 1.1 651
7 41 6.3 651
8 129 19.8 651
9 174 26.7 651
10 (very easy) 252 38.7 651
Did you administer the injections yourself during this
treatment cycle?
Yes, completely 454 70.4 645
Yes, some injections 185 28.7 645
No 6 0.9 645
N/A 18
Did you use the follitropin-alpha pen (self-injection) outside
the home?
Yes, I have injected
outside the home
116 17.8 651




If Yes, how convenient was it to carry the follitropin-alpha pen with you?
Very good 49 43.0 114
Good 60 52.6 114
Bad 5 4.4 114
How confident did you feel that you accurately administered your
daily dose using the follitropin-alpha pen during this treatment?
Very confident 283 43.8 646
Somewhat confident 357 55.3 646
Not at all confident 6 0.9 646
N/A 17
How painful was the injection with the follitropin-alpha pen 0 (no pain) 139 21.2 657
1 236 35.9 657
2 123 18.7 657
3 77 11.7 657
4 21 3.2 657
5 36 5.5 657
6 13 2.0 657
7 5 0.8 657
8 4 0.6 657
9 2 0.3 657
10 (most pain) 1 0.2 657
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Table 2 Ease of use and level of satisfaction* (Continued)
Which was less painful; follitropin-alpha pen or other product? Follitropin-alpha pen 347 89.0 390
Same 39 10.0 390
Other product 4 1.0 390
N/A or No use of
other product
273
Overall, how satisfied are you with the follitropin-alpha pen Satisfied 521 80.2 650
Neither satisfies or not
satisfied
124 19.1 650
Not satisfied 5 0.8 650
N/A 13
How would you rate the overall level of satisfaction when using
the follitropin-alpha pen?
1 (not satisfied at all) 4 0.6 651
2 2 0.3 651
3 4 0.6 651
4 5 0.8 651
5 34 5.2 651
6 18 2.8 651
7 42 6.5 651
8 141 21.7 651
9 153 23.5 651
10 (very satisfied) 248 38.1 651
Based on your experience, would you recommend follitropin-alpha
pen to another woman considering fertility treatment?
Yes 596 93.9 635
No 39 6.1 635
N/A 28
*Patients were asked a series of questions to assess how easy it was to use the follitropin-alpha (FbM) prefilled pen and to assess overall levels of satisfaction with
the pen. N/A = patient did not answer the question.
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Women receiving OI or ART fertility treatment with the
follitropin-alpha (FbM) prefilled pen in their current treat-
ment cycle were eligible for inclusion in the study.
No further inclusion or exclusion criteria were used.
Patients from 23 JISART-certified clinics were
recruited into the study over 14 months from Octo-
ber 2009 to December 2010, with a target recruit-
ment number of 650.
Assessment
Patients undergoing treatment with the follitropin-alpha
(FbM) prefilled pen were asked to complete a question-
naire to assess their ease of learning and use, injection
site pain and overall satisfaction. The first part of the
questionnaire was completed after appropriate instruc-
tion was given for the patients to learn how to use the
device and included 7 multiple-choice questions that
were associated with how easy patients found it to learn
to use the follitropin-alpha (FbM) prefilled pen. The sec-
ond part of the questionnaire, completed at the end of
the treatment, consisted of 10 questions that assessed
how easy patients found the pen to use, how painfulpatients found the pen and the patients’ overall satisfac-
tion with the pen. If a patient had experience in previous
treatment cycles of using formulations of FSH other
than follitropin-alpha, with different methods of admin-
istration, she was asked to compare the follitropin-alpha
(FbM) prefilled pen with the previous therapy. This sec-
tion of the questionnaire enabled comparison of the
follitropin-alpha (FbM) prefilled pen with other systems
of gonadotrophin administration. The scoring system for
the questionnaire ranged from 1 to 10 for ease of learn-
ing and use, as well as overall satisfaction with a score of
10 reflecting the most positive experience. The scoring
for injection site pain also ranged from 1 to 10 on a nu-
merical rating scale, with 10 being the most painful
experience.
Reporting methods
Patient responses were calculated as a percentage of the
population who responded to each question. Studies that
use patient questionnaires to gather information invari-
ably have some data missing from the completed forms.
In these cases, the responses were not included in the
final analysis.
Figure 1 Ease of use. Pie chart shows the percentage of patients
responding by category to the question ‘How easy was it for you to
use the follitropin-alpha pen?’ (n=663).
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Patient and treatment characteristics
A total of 663 women who were prescribed follitropin-
alpha (FbM) prefilled pen (OI = 39.4%, n = 261/663;
ART = 60.6%, n = 402/663) at 23 JISART-certified
clinics were recruited into the study. The majority of
participating women self-administered their injections
(68.5%; n = 454/663) or partly self-administered their
injections (27.9%; n = 185/663).
Ease of learning
A total of 663 women who were receiving treatment with
the follitropin-alpha (FbM) prefilled pen in their current
treatment cycle participated in the questionnaire-based
study. Patients were asked a series of questions to assess
how easy it was to learn to use the follitropin-alpha (FbM)
prefilled pen and a full list of questions and tallied
responses are shown in Table 1.
The majority of patients surveyed (83.0%; n = 546/658)
found the instructions for administering follitropin-alpha
with the prefilled pen easy to understand and patients gave
an average score of 8.54 out of 10 for ease of learning (1 =
difficult to understand; 10 = easy to understand). Several
tools were employed to teach patients how to use the
follitropin-alpha (FbM) prefilled pen, including doctor/
nurse’s guidance, a printed leaflet, a DVD video and a
website page. Women found doctor/nurse’s guidance
(91.5%; n = 582/636), a printed leaflet (71.1%; n = 421/
592) and DVD (47.3%; n = 160/338) were the most effect-
ive learning tools, whereas the majority of patients did not
use, or did not confirm whether they had used, the website
page as a training aid (89.6%; n = 594/663) or did not find
it useful (43.5%; n = 30/69). Overall, 80.0% (n = 497/621)
of patients found that a hands-on demonstration by a
nurse or doctor was the most useful training tool, 14.3%
(n = 89/621) found a printed leaflet was the most useful
tool and 5.6% (n = 35/621) found a DVD the most useful,
whereas no women found the website page to be the most
useful tool.
Forty-eight percent of patients in the study had previous
experience with gonadotropin medications, other than folli-
tropin-alpha, for the treatment of infertility. These were the
follitropin-beta pen (rFSH, Follistim cartridge-type pen;
Organon, Roseland, NJ, USA; 40.9%; n = 130/318), hMG
(vial, ampoule and syringe; 37.4%; n = 119/318), follitropin-
beta vial (rFSH, Follistim vial; Organon, Roseland, NJ, USA;
16.7%; n = 53/318), Folyrmon P (uFSH, ampoule and
syringe; Fuji Seiyaku Kogyo, Chuo-ku, Tokyo, Japan; 3.1%;
n = 10/318) and Gonapure (uFSH, ampoule and syringe,
ASKA Pharmaceutical, Tokyo, Japan; 1.9%; n = 6/318).
When questioned if they found the follitropin-alpha (FbM)
prefilled pen easier to learn to use than a previous treat-
ment, 75.1% (n = 232/309) of patients stated that
follitropin-alpha was easier to use, 22.7% (n = 70/309)thought there was no difference in ease of use between
treatments and 2.3% (n = 7/309) believed their previous
treatment was easier to use. When patients were ques-
tioned as to whether they would recommend the
follitropin-alpha (FbM) prefilled pen to another woman
considering fertility treatment based on how easy they
found it to learn to use, the majority of patients
said they would recommend follitropin-alpha (94.9%;
n = 611/644).
Ease of use and injection site pain
Patients were also asked a series of questions to assess
how easy they found the follitropin-alpha (FbM) prefilled
pen to use and their overall satisfaction with the device
(Table 2). Patients gave an average score of 8.65 out of
10 for ease of use (1 = difficult to use; 10 = easy to use).
Almost all of the patients responded that the follitropin-
alpha (FbM) prefilled pen was very easy to use (78.9%;
n = 514/651) or that they had little difficulty in self-
injection (19.2%; n = 125/651) (Figure 1), and 99.1% (n =
639/645) of the women were able to administer some or
all of their own injections with the follitropin-alpha
(FbM) prefilled pen. Seventy-five percent (232/309) of
women who had prior experience of other treatments
for infertility found injection with the follitropin-alpha
(FbM) prefilled pen easier to learn to use than the prior
therapy.
When questioned how painful they found injection
with the follitropin-alpha (FbM) prefilled pen, almost a
quarter of respondents said they experienced no pain
(score of 0; 20.9%; n = 137/657) and a little pain was
reported by the majority of patients (score of between
0.5 and 4; 69.9%; n = 459/657) (Figure 2). Among the
patients who had prior experience of other treatments
for infertility, 89.0% (n = 347/390) found follitropin-
alpha to be less painful to use than the other treatment.
Figure 2 Injection site pain during use. Pie chart shows the
percentage of patients responding by category to the question
‘How painful was the injection with the Gonal-f pen?’ (n=663).
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The majority (80.2%; n = 521/650) of women reported
being satisfied with their treatment experience using the
follitropin-alpha (FbM) prefilled pen compared with
19.1% (n = 124/650) who were neither satisfied nor dis-
satisfied and 0.7% (n = 5/650) who were not satisfied
(Figure 3). The follitropin-alpha (FbM) prefilled pen
received an average score of 8.6 out of 10 (1 = not satis-
fied; 10 = very satisfied). Nearly all (93.9%; n = 596/635)
of survey respondents said they would recommend using
the follitropin-alpha (FbM) prefilled pen to another
woman considering fertility treatment. Patients who
found the follitropin-alpha (FbM) prefilled pen easy to
learn and use demonstrated the highest overall satisfac-
tion (Figure 4). However, there was no direct correlation
between ease of learning and use, and overall satisfac-
tion. Additionally, patients who experienced little pain at
the injection site when using the follitropin-alpha (FbM)
prefilled pen had higher overall satisfaction than patients
who experienced pain at the injection site (Figure 5).Figure 3 Level of patient satisfaction. Pie chart shows the
percentage of patients responding by category to the question
‘How would you rate the overall level of satisfaction when using the
follitropin-alpha pen?’ (n=663).Discussion
The results from this questionnaire-based survey—which
involved 663 women and was the largest of its type to be
performed in Japan—show that the majority of patients
found the follitropin-alpha pen easy to learn, to use and
to administer with minimal pain experienced at the in-
jection site. Higher overall patient satisfaction appeared
to be associated with higher scores for ease of learning
and use, as well as less pain at the injection site, al-
though no direct correlation between these factors was
found. Seventy-five percent (232/309) of patients who
had experience of other treatments for infertility found
the follitropin-alpha (FbM) prefilled pen the easiest
product to use and almost all would recommend the use
of the follitropin-alpha pen to other women. These
results are comparable to those from two other studies
reported in a single publication by Porter et al. [14]. The
first was a 2-year observational study conducted in
Germany, which found that patients favoured treatment
with the follitropin-alpha (FbM) prefilled pen over the
follitropin-beta pen due to faster preparation, greater
confidence in dosing accuracy and the need for fewer
dose adjustments [14]. In the second study, conducted
in Australia, patients again favoured the follitropin-alpha
(FbM) prefilled pen over the follitropin-beta pen for the
same reasons. Additionally, patients experienced less
injection site pain with the follitropin-alpha (FbM)
prefilled pen than with the follitropin-beta pen [14]. A
larger questionnaire-based study of 5328 patients under-
going ART in Germany reported that the routine use of
the follitropin-alpha (FbM) prefilled pen was well
accepted by patients [13]. In this study, patients found
the follitropin-alpha (FbM) prefilled pen easier to learn
to use than other injection methods and reported it as
their preferred method of FSH administration [13].
The current study included an exploration of patients’
views on the different tools provided to teach them how to
use the follitropin-alpha (FbM) prefilled pen. Surprisingly,
web-based training was not widely utilised and was asso-
ciated with lower overall satisfaction than the other train-
ing tools. Patients found hands-on demonstration by a
doctor or nurse to be the most useful tool for learning how
to use the follitropin-alpha (FbM) prefilled pen. When a
healthcare professional demonstrates how to perform the
injection, patients have the chance to ask any questions
they may have on correct administration and what they
should do if they encounter any problems. Asking a doctor
or nurse can provide patients with the reassurance that
they need to correctly administer the treatment at home by
themselves. Interestingly, nurses have also reported very
high levels of satisfaction with their experiences of teaching
patients to use the follitropin-alpha pen [14].
One of the advantages of a ready-to-use device is that it
reduces the chances of a reconstitution error occurring.
Figure 4 Ease of learning, ease of use and overall satisfaction. Patients were asked to rate the ease of learning, ease of use and overall
satisfaction with the follitropin-alpha pen on a scale of 1 to 10 (n = 663).
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bility of both injection and dosing errors, which could po-
tentially affect patient confidence in the device as well as
the choice of device used in fertility programmes. Add-
itionally, increased patient confidence, dosing consistency
and dosing accuracy are key requirements for a drug deliv-
ery device to allow physicians to maximise the predictabil-
ity of ovarian stimulation and success [10].
When questioned, over three quarters of the patients
in the study who had previous experience of other go-
nadotrophin formulations and devices found the
follitropin-alpha pen easier to use and reported less in-
jection site pain than with other products. Of note, in a
study of patients receiving human growth hormone
injections, the five key delivery device attributes identi-
fied by patients were reliability, ease of use, lack of pain,
safety in use and a small number of steps required for
preparation [16]. The follitropin-alpha (FbM) prefilled
pen encompasses all of these attributes. Also worthy of
consideration is that the introduction of insulin self-
injection pens for patients with diabetes led to an im-
provement in patient compliance and treatment out-
comes, with patients reporting that they found injection
pens less painful than syringes and needles [17-22]. It isFigure 5 Injection site pain and overall satisfaction. Patients were aske
follitropin-alpha (FbM) pen on a scale of 1 to 10 (n = 663).likely that the use of injection pens for infertility treat-
ment that cause less injection site pain than conven-
tional syringes will have a similar positive effect on
compliance. It has also been demonstrated in many
therapeutic areas that increasing patient information
leads to increased patient satisfaction and adherence to
treatment [23-26].
Additionally, it has been suggested that the efficacy of
ovarian stimulation regimens may improve with the use of
injection pen devices compared with conventional syr-
inges. This could be due to several factors such as
increased adherence to treatment and also the correct ad-
ministration and dosing of treatment. However, further
evidence is required to support these claims [27-29].
In summary, the follitropin-alpha (FbM) prefilled pen is
an easy-to-use injection device and offers reduced injec-
tion site pain compared with conventional devices. A high
level of overall patient satisfaction with the follitropin-
alpha (FbM) prefilled pen was documented in this study
involving 23 JISART-certified fertility centres in Japan.
The results of this survey are in agreement with previous
findings confirming the ease of learning and use of the
pen in both previously untreated patients and patients
with previous experience of other fertility treatments.d to rate the injection site pain and overall satisfaction with the
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